Finally, by linking muscle indices with nutritional/metabolic markers (albumin, calcium, and transaminases) and conducting analyses under standardized supportive-care protocols, we provide biologically coherent and clinically actionable signals that can inform pre-transplant risk stratification and targeted optimization (e.g., metabolic and anemia management) in patients considered for HDCT/ASCT. The gene discussed is ALB; the disease is anemia.